RIVAROXABAN VIATRIS
As listed in the register: RIVAROXABAN VIATRIS 20 mg, comprimé pelliculé
20 mg · comprimé pelliculé
- Prescription only
- Active substance
- Rivaroxaban
- Made by
- VIATRIS (IRLANDE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (rivaroxaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
XARELTO is a selective inhibitor of FXa.
It does not require a cofactor (such as Anti-thrombin III) for activity.
Unchanged drug is excreted into urine, mainly via active tubular secretion and to a lesser extent via glomerular filtration (approximate 5:1 ratio).
For the 2.5 mg and 10 mg dose, it is estimated to be 80% to 100% and is not affected by food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-10
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (rivaroxaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A.
- XARELTO is contraindicated in patients with: active pathological bleeding [see Warnings and Precautions (5.2) ] severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) [see Adverse Reactions (6.2) ] Active pathological bleeding ( 4 ) Severe hypersensitivity reaction to XARELTO ( 4 )
The most common adverse reactions with XARELTO were bleeding complications [see Warnings and Precautions (5.2) ].
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States7 matching products
Bulgaria20 matching products
- Polbaxan 20 mg · film - coated tablets2 makers
- Thinban Thinban 20 mg film-coated tablets · film - coated tablets2 makers
- Enkia 20 mg · film - coated tablets
- KARDATUXAN 20 mg · film - coated tablets
- Rivaroxaban Grindeks 20 mg · film - coated tablets
- Rivaroxaban MSN 20 mg · film - coated tablets
- Rivaroxaban Teva 20 mg · film - coated tablets
- Rivaroxaban-Tchaikapharma 20 mg · film - coated tablets
European UnionNo exact match for this strength and form
Canada22 matching products
Netherlands32 matching products
- Rivaroxaban Sandoz 20 mg 20 mg · filmomhulde tablet4 makers
- Blomensy 20 mg filmomhulde tabletten 20 mg · filmomhulde tablet
- Rivaroxaban Accord 20 mg filmomhulde tablet 20 mg · filmomhulde tablet
- Rivaroxaban AET 20 mg 20 mg · filmomhulde tablet
- Rivaroxaban Amarox 20 mg 20 mg · filmomhulde tablet
- Rivaroxaban Ascend 20 mg filmomhulde tabletten 20 mg · filmomhulde tablet
- Rivaroxaban Aurobindo 20 mg 20 mg · filmomhulde tablet
- Rivaroxaban CF 20 mg 20 mg · filmomhulde tablet
Details
| Made by | VIATRIS (IRLANDE) |
|---|---|
| Active substance | Rivaroxaban |
| Strength | 20 mg |
| Form | comprimé pelliculé |
| Route | orale |
| Dispensing (as stated by the register) | liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/21/1588 |
| Name in the register | RIVAROXABAN VIATRIS 20 mg, comprimé pelliculé |
| Packs | plaquettes PVC PVDC aluminium de 28 comprimés (calendaire) · 1 flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) · 100 plaquettes PVC PVDC aluminium de 1 comprimé (dose unitaire) |
| CIS | 61186021 |
| CIP13 | 3400930276211 |
| CIP13 | 3400930301517 |
| CIP13 | 3400955094142 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.